HELP

Cybin Inc. operates as a biopharmaceutical company focused on developing psychedelic-based therapeutic programs for mental health conditions. Headquartered in Toronto, Canada, the company advances a pipeline of proprietary molecules and drug delivery systems designed to address major depressive disorder, alcohol use disorder, and anxiety disorders. Cybin's lead investigational program, CYB003, is a deuterated psilocybin analog in Phase 3 clinical trials for major depressive disorder, representing one of the most advanced psilocybin programs globally. The company also develops CYB004, a deuterated dimethyltryptamine (DMT) molecule with a proprietary inhalation delivery system for generalized anxiety disorder and other potential indications. The company maintains research and development operations in both Canada and the United Kingdom, with clinical trial activities conducted across multiple international sites. Cybin's business model centers on advancing its proprietary compounds through clinical development, leveraging novel formulations and delivery technologies to differentiate from naturally occurring psychedelics. In 2021, the company acquired Adelia Therapeutics, expanding its therapeutic pipeline and intellectual property portfolio. Cybin trades on the NYSE American exchange and has established partnerships with contract research organizations and clinical sites to support its development programs. The company employs approximately 80 professionals and maintains a focus on regulatory pathways toward potential commercial approval of psychedelic therapeutics.